ADC Related Compound

ADC drugs are targeted drugs formed by coupling monoclonal antibodies with small molecule toxin drugs through linkers. ADC consists of three parts: antibodies, small molecule toxins and linkers. Each component needs to have corresponding characteristics. The antibody needs to have high specificity and low immunogenicity; the linker needs to be stable in the circulatory system and can effectively release cytotoxins in the tumor environment, and the small molecule toxin needs to be stable under physiological conditions and have strong lethality to tumor cells; the ideal ADC drug needs to remain stable in the blood circulation, accurately reach the treatment target, and ultimately release cytotoxicity near the target.